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Abstract: Although 4-O-Methylhonokiol (MH) effects on neuronal and immune cells have been
established, it is still unclear whether MH can cause a change in the structure and function of
the cardiovascular system. The overarching goal of this study was to evaluate the effects of MH,
isolated from Magnolia grandiflora, on the development of the heart and vasculature in a Japanese
medaka model in vivo to predict human health risks. We analyzed the toxicity of MH in different
life-stages of medaka embryos. MH uptake into medaka embryos was quantified. The LC50 of two
different exposure windows (stages 9–36 (0–6 days post fertilization (dpf)) and 25–36 (2–6 dpf))
were 5.3 ± 0.1 µM and 9.9 ± 0.2 µM. Survival, deformities, days to hatch, and larval locomotor
response were quantified. Wnt 1 was overexpressed in MH-treated embryos indicating deregulation
of the Wnt signaling pathway, which was associated with spinal and cardiac ventricle deformities.
Overexpression of major proinflammatory mediators and biomarkers of the heart were detected.
Our results indicated that the differential sensitivity of MH in the embryos was developmental
stage-specific. Furthermore, this study demonstrated that certain molecules can serve as promising
markers at the transcriptional and phenotypical levels, responding to absorption of MH in the
developing embryo.
Keywords: cardiomyogenesis; factor VII; factor X; inflammation; thrombosis; vasculogenesis;
herbal medicine
1. Introduction
Magnolia bark extract has been used as a component of dietary supplements and cosmetic
products [1]. One specific compound found in Magnolia species, 4-O-Methylhonokiol (MH),
is recognized to have multifunctional activities both in vitro and in vivo, similarly to other honokiol
analogs [2,3]. Magnolias appear to naturally produce a significant amount of these biphenyl-type
neolignan compounds, many of which show tissue specific distribution [4]. MH is expressed
throughout the plant, with high amounts found in the leaves and seeds [5], whereas honokiol
with its isomer magnolol are largely limited to the bark [6]. MH and 2-O-Methylhonokiol are
isomers [7]. The optimal ratio of these two isomers and their mechanism of synthesis have not
been fully characterized. Moreover, the effects of MH on the cardiovascular system remain poorly
understood. Due to its low hydrophilicity, MH exhibits poor pharmacokinetics [8], which may lead to
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increased accumulation in the organs of the body. Some evidence has suggested beneficial effects of
MH, as it has been associated with anti-inflammatory [9], anti-osteoclastogenic, anti-oxidative [10,11],
and neuroprotective [12] effects. Considering the apparent non-specificity of these effects, it is likely
that MH has low targeting efficacy and exerts its cellular protective properties through a wide range of
mechanisms. In contrast to the observed beneficial effects, the co-treatment of compounds with MH
counterparts, both magnolol and honokiol, can exert synergistic cytotoxicity [13]. The incongruity
between the protective and detrimental effects of MH thus far in the literature highlights the importance
of understanding how MH or other compounds extracted from magnolia affect the development and
function of tissues and organs, like the cardiovascular system.
Both angiogenesis and vasculogenesis (de novo blood vessel formation from embryonic
precursors) have many features in common, and impairment of these processes can in turn cause
damage to organs and influence blood circulation. We aim to identify exposure windows, which can
provide insight into the potentially toxic effects of MH on the development of the heart, angiogenesis,
and vasculogenesis, beyond its other potential action on multiple sites through different toxicity
pathways. Identifying the critical stage of MH-induced cardiovascular toxicity lays down a basis for
further elucidation of an adverse outcome pathway for MH and provides a starting point for future
studies on the mechanisms of MH toxicity.
Due to its inherent low concentration in plant extracts containing honokiol and magnolol, MH has
not been fully characterized. MH, like propofol, has a phenol ring, which produces side effects
causing hypertension and altering both heartbeat and heart rate. Since magnolia bark extract is
gaining widespread popularity as a preventive and alternative to medical treatments [14,15], it is
vital to understand the molecular mechanisms of MH and characterize whether it causes embryotoxic
and teratogenic effects in the cardiovascular system in a variety of vertebrates. By accounting for
heterogeneities typical of Japanese medaka (Oryzias latipes), which shares 58% homology with its
human counterpart, our first vertebrate model for the embryonic lethality of MH enables us to
investigate the effects of MH on the embryo’s developing heart and deformities, as well as alterations
in inflammatory and parameters of coagulation.
In this study, we assessed the toxicity of MH in different life-stages of the medaka cardiovascular
system. We hypothesized that the differential susceptibility of the stage-specific embryo might identify
critical exposure windows to MH, which could in turn produce lethal and sublethal thresholds for
toxicity because of differences in uptake of MH and subsequent internal concentrations.
2. Results
2.1. Toxicity of MH in Medaka Embryo
The toxicity of MH exposure on medaka was assessed at various stages of development (see
MH-treatment in Materials and Methods section). While 10 µM MH was not toxic to embryos after 48 h,
it caused 70% mortality within 96 h. A full concentration-response analysis of toxicity following six
days of MH exposure time point revealed significant mortality of MH-treated medaka embryo/larvae
(LC50 = 5.3± 0.1 µM) (Figure 1A). Larval toxicity was also evident, with the most common effects being
spine malformations and edema. Observation of overall mortality with increasing concentrations over
time revealed a reduction in larval survivability following exposure to concentrations of 2 µM MH and
higher (Figure 1B). Some spinal deformities were observed in the larvae (Appendix A, Figure S1 under
Supplementary Materials) which were associated with 5 µM and 10 µM MH. Embryos exposed to
10 µM MH showed delayed growth and high mortality rates during late larval- and juvenile-life stages.
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Figure 1. Cumulative mortality of medaka embryos. Embryos were exposed to 1, 2, 5, 10, and 20 μM 
4-O-Methylhonokiol (MH) for 0–6 days post fertilization (dpf) (A and B) or 2–6 dpf (C and D). (A) 
Embryos were treated with MH for six days from hour 5, and the LC50 was calculated based on 
mortality observed at 10 dpf. (B) Cumulative mortality of all embryos until 10 dpf treated with various 
concentrations of MH for 0–6 dpf. (C) Embryos were treated with MH for four days from 2 dpf and 
the LC50 was calculated based on mortality observed at 10 dpf. (D) Cumulative mortality until 10 dpf 
of all embryos treated with various concentrations of MH for 2–6 dpf. The LC50 was calculated by log 
transformed data using nonlinear regression (curve-fit) (GraphPad Prism). Each value represents 
mean ± SEM (n = 12, replicated five times). (E) The relationship between MH concentration and mean 
adult medaka mortality. Eighteen male medakas were randomly divided into three groups (n = 6). 
They were exposed to 1 or 5 μM MH, and monitored for 96 h. Controls were exposed to 0.02% DMSO. 
A second batch of embryos exposed to MH later in development (2–6 dpf) also exhibited 
concentration-dependent toxicity (10 dpf, LC50 = 9.9 ± 0.2 μM) (Figure 1C). Like the first batch of 
embryos, survivability was significantly reduced in later-staged larvae exposed to 10 and 20 μM 
(Figure 1D). There was a direct relationship between the changes in MH concentration and changes 
in hatching efficiency. Behavioral alterations such as difficulty in swimming and equilibrium loss 
were seen with both 5 μM MH and 10 μM MH. However, while termination from MH treatment 
allowed 5 μM MH-treated embryos to recover normal behavior, stopping MH treatment at 6 dpf from 
hour 5 was ineffective in the 10 μM MH group. The control group treated with DMSO, ranging from 
0.02 to 0.04%, exhibited normal embryo development and normal hatching. Embryo mortality for this 
group was always below 10%, contrasting clearly with the experimental groups. The sensitivity of 
adult medaka to MH toxicity was then assessed. Exposure of 5 μM MH in adults caused 65% 
mortality within 24 h, whereas both the control group and fish exposed to 1 μM MH survived (Figure 
1E). The survival time of 5 μM MH was significantly less than that of 1 μM MH-immersed adult 
medaka. This result demonstrates that 5 μM MH reduces survivability in the adult medaka model 
and further underscores its importance for additional health-related research.  
The membrane penetration properties of MH on the medaka chorion are unknown. Although 
the chorion of the egg acts as a barrier within the embryo, the 80% mortality of embryos indicated an 
incorporation of MH into the egg. Mass spectrometry analysis of MH levels in conditioned growth 
media from the medaka revealed that the concentrations of MH decreased to non-detectable levels 
from time 0 h to 24 h (Figure 2A,B). However, a second molecule with a retention time of 2.628 min 
was present following 24 h incubation when MS was operated in scan mode (Figure 2C).  
Since the molecular and biochemical basis of formation of this molecule from MH is unknown, the 
identity of this unknown molecule was not characterized. Nevertheless, incubation of embryos with 
Figure 1. Cumulative mortality of medaka embryos. Embryos were exposed to 1, 2, 5, 10, and 20 µM
4-O-Methylhonokiol (MH) for 0–6 days post fertilization (dpf) (A,B) or 2–6 dpf (C,D). (A) Embryos were
treated with MH for six days from hour 5, and the LC50 was calculated based on mortality observed
at 10 dpf. (B) Cumulative mortality of all embryos until 10 dpf treated with various concentrations
of MH for 0–6 dpf. (C) Embryos were treated with MH for four days from 2 dpf and the LC50 was
calculated based on mortality observed at 10 dpf. (D) Cumulative mortality until 10 dpf of all embryos
treated with various concentrations of MH for 2–6 dpf. The LC50 was calculated by log transformed
data using nonlinear regression (curve-fit) (GraphPad Prism). Each value represents mean ± SEM
(n = 12, replicated five times). (E) The relationship between MH concentration and mean adult medaka
mortality. Eighteen male medakas were randomly divided into three groups (n = 6). They were exposed
to 1 or 5 µM MH, and monitored for 96 h. Controls were exposed to 0.02% DMSO.
A second batch of embryos exposed to MH later in development (2–6 dpf) also exhibited
concentration-dependent toxicity (10 dpf, LC50 = 9.9 ± 0.2 µM) (Figure 1C). Like the first batch
of embryos, survivability was significantly reduced in later-staged larvae exposed to 10 and 20 µM
(Figure 1D). There was a direct relationship between the changes in MH concentration and changes in
hatching efficiency. Behavioral alterations such as difficulty in swimming and equilibrium loss were
seen with both 5 µM MH and 10 µM MH. However, while termination from MH treatment allowed
5 µM MH-treated embryos to recover normal behavior, stopping MH treatment at 6 dpf from hour 5
was ineffective in the 10 µM MH group. The control group treated with DMSO, ranging from 0.02
to 0.04%, exhibited normal embryo development and normal hatching. Embryo mortality for this
group was always below 10%, contrasting clearly with the experimental groups. The sensitivity of
adult medaka to MH toxicity was then assessed. Exposure of 5 µM MH in adults caused 65% mortality
within 24 h, whereas both the control group and fish exposed to 1 µM MH survived (Figure 1E).
The survival time of 5 µM MH was significantly less than that of 1 µM MH-immersed adult medaka.
This result demonstrates that 5 µM MH reduces survivability in the adult medaka model and further
underscores its importance for additional health-related research.
The membrane penetration properties of MH on the medaka chorion are unknown. Although
the chorion of the egg acts as a barrier within the embryo, the 80% mortality of embryos indicated an
incorporation of MH into the egg. Mass spectrometry analysis of MH levels in conditioned growth
media from the medaka revealed that the concentrations of MH decreased to non-detectable levels
from time 0 h to 24 h (Figure 2A,B). However, a second molecule with a retention time of 2.628 min
was present following 24 h incubation when MS was operated in scan mode (Figure 2C). Since the
molecular and biochemical basis of formation of this molecule from MH is unknown, the identity of
this unknown molecule was not characterized. Nevertheless, incubation of embryos with MH for 24 h
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led to 100% MH disappearance from the media (Figure 2D), suggesting either uptake of MH into the
fish and/or degradation of the molecule.
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2.2. Exposure to MH during Early Development Affects Cardiovascular Structure and Function
Cardiovascular changes in response to MH were then assessed. We demonstrated here that MH
treatment resulted in reduced blood flow which peaked at around an 80% decrease with 10 µM MH at
the end of the 0–6 dpf treatment session (Figure 3A). The reductions in blood flow were associated
with corresponding changes in blood vessel occlusion (Figure 3B). Reduced blood flow (Figure 3C)
and blood vessel occlusion (Figure 3D) were noticeable in the 2–6 dpf embryos also, at the same
concentrations as compared to those of control embryos from day six (stages 36–38).
As shown in Figure 4A, the resting heart rate for both the control and DMSO-treated (0.02%)
embryos increased with development. MH-treated embryos had lower heart rates than the control
group at three-days and six-days post-treatment. MH treatment was effective in reducing the heart-beat
of late embryos (6 dpf) (p ≤ 0.05, n = 27) by 9%, suggesting MH influences the normal functioning
of the heart. High-speed time-lapse analysis of the heartbeat showed that bradycardia occurred in
the 0–6 day embryos treated with 10 µM MH when treatments were initiated early (from hour 5)
(Figure 4B,C; see videos for better visualization of the differences in heart malfunction between the
control (video 1) and MH-treated embryo (video 2) in Appendix B under Supplementary Materials).
The average heart rate and blood flow for the 10 µM MH-treated embryos were lower than for the
DMSO-treated controls.
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10 µM MH from 5 h post fertilization (hpf) to 6 dpf (0–6 dpf, (A,B)) or from 2 dpf to 6 dpf (2–6 dpf, (C,D)).
This figure showed that the reduction in blood flow was proportionally correlated with blood vessel
occlusion. (A) Blood flow was observed on days 2, 3, 4, 5, and 6 to verify the duration of the reduction of
blood flow. This panel ex mplifies the percent reducti n in blood flow until 10 dpf in response to various
concentrations of MH for 0-6 dpf. (B) This panel shows percent occlusion following MH treatment.
During the treatment, blood flow was significantly reduced compared to the control immediately after
occlusion. (C) Thirty-two embryos (2 dpf) were randomly divided into four groups (n = 8). Embryos
were treated with the indicated co centrations of MH and 0.02% DMSO (control) in embryo medium and
were maintained at 26 ± 1 ◦C for 4 days. This figure shows reduced blood flow in MH-treated embryos
(2–6 dpf). (D) This figure demonstrates a blockage that prevents normal flow of blood for the MH-treated
embryos ex sed to various conce trations of MH from 2 pf to 6 dpf. Each ba represents data pooled
from 4–5 independent experiments. Statistical analysis was performed by one-way analysis of variance
(ANOVA) followed by Tukey’s post-hoc multiple comparison test. p < 0.05 was considered as significant.
The asterisk (*) indicates values significantly different from the control.
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Figure 4. MH is responsible for the defect in cardiac function in vivo. Embryos were exposed to 10 µM
MH or 0.02% DMSO (which was used as solvent in the treated condition) as the control from 5 hpf to
6 dpf. Heartbeat, blood flow, and heart structure were evaluated. (A) Heart beat was recorded and
expressed as beats per min. Bar graphs of results obtained by counting heart beats. Results are given
as the mean percentage of heart beat ± SEM (n > 8 embryos for each condition). Statistical analysis
was performed by one-way ANOVA followed by Tukey’s post-hoc multiple comparison test (p < 0.05).
(B) Representative image of heart function in the control. (C) Representative bright field images of
MH-induced heart ventricle malfunction in embryos treated with 10 µM MH for six days from hour 5.
See videos for better visualization of the differences in h art malfunction betwee the control (video 1)
and MH-treated embryo (video 2). Images were acquired on a Nikon TI2-E inverted microscope with a
white light LED illuminator and a sCMOS Cooled Monochrome Camera. Videos were captured using
a Nikon Elements automated acquisition device.
Molecules 2019, 24, 475 6 of 21
2.3. MH Is Implicated in Cardiovascular Dysfunction
To examine the mechanism of these vascular changes, expression levels of three key coagulation
factors, factor XI (FXI, a protease of intrinsic pathway), factor VII (FVII, a protease of extrinsic pathway),
and factor X (FX, a protease of common pathway) were quantified (Figure 5A). These factors are
essential for hemostasis and indispensable for thrombosis. FXI, FX, and FVII circulate in the blood
in zymogen forms. Activation of them leads to the formation of blood clots. As shown in Figure 5,
these three protease transcripts were significantly (p ≤ 0.05, n = 100, replicated four times) elevated in
embryos treated with 10 µM MH for six days from hour 5.
Since MH reduced blood flow (Figure 3A,C), we hypothesized that the reduced blood flow
activated the endothelium to synthesize and release tissue plasminogen activator (tPA, a fibrinolytic
peptide) and plasminogen activator inhibitor 1 (PAI-1, a prothrombotic peptide) and thus decrease the
ratio of tPA/PAI-1, ultimately promoting thrombosis. PAI-1 cDNA product was significantly elevated
at the mRNA level with 10 µM MH, while tPA and endothelin B mRNA levels were not altered
(Figure 5A). However, the ratio of the steady-state tPA/PAI-1 mRNA was significantly decreased in the
embryos, suggesting increased levels of fibrin fragments, as previously described [16]. We measured
the quantitative expression pattern of urokinase plasminogen activator (uPA) in 0–6 day embryos
treated with 10 µM MH from hour 5. uPA mRNA levels were significantly increased (Figure 5A).
To confirm that vascular endothelial cells are activated in response to MH, we examined the expression
profiles of endothelin B receptors that are located primarily in vascular endothelial cells and angiotensin
II type 1 receptor-associated protein (ATRAP), which is highly expressed in the kidney [17] and large
vessel [18]. Vascular expression of ATRAP was significantly enhanced in response to MH (Figure 5A).
Taken together, the data of Figure 5 demonstrated a previously unrecognized effect of MH on the
control of the cardiovascular system and suggested that FXI, FX, FVII, PAI-1, uPA, and ATRAP are
targets of MH.Molecules 2019, 24 FOR PEER REVIEW  7 
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associated protein (ATRAP) isolated from control and MH-treated embryos. (B) RT-qPCR analysis of 
natriuretic peptide A, Troponin T, ErbB3, and Nrg2. Data were normalized to the eukaryotic 
elongation factor 1-alpha (eEf1α) polymerase chain reaction signal. Each value represents mean ± SEM 
(n = 100, replicated four times). * indicates a value is significant versus the respective control group (p 
< 0.05). 
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expression of brain natriuretic peptide A and troponin T (Figure 5B). Further investigations were 
performed to explore the effect of MH on Nrg-2 and ErbB3, the molecules involved in the synthesis 
of acetylcholine at the neuromuscular junction [19]. Nrg-2, a cardiac chamber maturation marker, 
and ErbB3, which is involved in proper heart morphogenesis and function, were attenuated (Figure 
5B). These findings conferred that the cardioprotective property of the Nrg molecule was 
compromised in the presence of MH. 
  
Figure 5. Embryos treated with H lead to altered cardiac biomarker gene expression and altered
expression of genes involved in thrombosis, fibrinolysis, and vascular tone. Real-time RT-qPCR was
performed on total RNA isolated from each group of embryos using described primers in Table 1
leading to the amplification of the target gene. (A) RT-qPCR analysis of factor XI (FXI), factor VII (FVII),
factor X (FX), plasminogen activator inhibitor 1 (PAI-1), tissue plasminogen activator (tPA), urokinase
plasminogen activator (uPA), endothelin B (ETB), and angiotensin type 1 receptor associated protein
(ATRAP) isolated from control and MH-treated embryos. (B) RT-qPCR analysis of natriuretic peptide
A, Troponin T, ErbB3, and Nrg2. Data were normalized to the eukaryotic elongation factor 1-alpha
(eEf1α) polymerase chain reaction signal. Each value represents mean ± SEM (n = 100, replicated four
times). * indicates a value is significant versus the respective control group (p < 0.05).
To further confirm that MH influences the normal functioning of the heart, we measured the
expression patterns of heart development-related genes. Controls were exposed to 0.01% DMSO for the
RT-qPCR study. After treatment with 10 µM MH, the embryos showed highly up-regulated expression of
brain natriuretic peptide A and troponin T (Figure 5B). Further investigations were performed to explore
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the effect of MH on Nrg-2 and ErbB3, the molecules involved in the synthesis of acetylcholine at the
neuromuscular junction [19]. Nrg-2, a cardiac chamber maturation marker, and ErbB3, which is involved
in proper heart morphogenesis and function, were attenuated (Figure 5B). These findings conferred that
the cardioprotective property of the Nrg molecule was compromised in the presence of MH.
2.4. MH Possesses the Proinflammatory and Pro-Oxidative Properties
We looked into the effect of MH on the expression levels of catalase, glutathione peroxidase
(GPX), glutathione-S-transferase (GST), and superoxide dismutase (SOD) (Figure 6). Forkhead
boxO1 (FoxO1) was overexpressed with 0–6 dpf MH exposure beginning from hour 5 (Figure 6).
Catalase, GPX, and GST mRNAs were significantly overexpressed, whereas SOD mRNA was not
statistically significant (Figure 6). This finding suggested that MH-dependent increased expression of
these anti-oxidant enzymes in the embryo was a mechanism by which they could eliminate excess
reactive oxygen species (ROS). Since the Wnt/β-catenin signaling pathway is capable of regulating
inflammatory cell migration and macrophage phenotypes in zebrafish [20], we then assessed the
expression profiles of tissue necrosis factor-alpha (TNF-α) and interleukin 1 beta (IL-1 β) (Figure 6).
Expression analysis showed significant upregulation of IL-1β and TNF-α in MH-treated embryos at
the transcription level (Figure 6). This observation suggests that the overexpression of FoxO1 might
cause a decrease in endothelial cell sprouting and migration, as seen in a previous report [21]. On the
basis of these results, MH appears to possess proinflammatory properties at the embryo level.
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Figure 6. Embryos treated with MH lead to altered expression of genes involved in cell regulation,
oxidative stress, and inflammation. Real-time RT-qPCR was performed on total RNA isolated from
each group of embryos using described primers in Table 1 leading to the amplification of the target gene.
RT-qPCR analysis of FoxO1, catalase, glutathione peroxidase (GPX2), glutathione-s-transferase (GSTA),
superoxide dismutase 2 (SOD-2), Interleukin 1 beta (IL-1β), and tissue necrosis factor-alpha (TNF-α)
isolated from control and MH-treated embryos. Data were normalized to the eEf1α polymerase chain
reaction signal. Each value represents mean ± SEM (n = 100, replicated four times). Statistical analysis
was performed by two-way ANOVA followed by post-hoc Bonferroni test. * indicates values which are
significant versus the respective control group (p < 0.05).
2.5. MH Reduces the Normal Hatching Process of Medaka Embryos
We hypothesized that decreased heart rate might reduce the embryos’ activity, leading to a reduction
in the distribution of nutrients and both coagulation and hatching enzymes, as has been previously
suggested [22]. To test this hypothesis, we explored the effects of MH on hatching. MH caused a
reduction in hatching in embryos exposed to 10 µM MH starting from the hours immediately after
fertilization (Figure 7A) or starting two days later (Figure 7B). Our findings demonstrate that MH can
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influence both early and late developmental stages of medaka, leading to reduced hatchability of eggs at
higher concentrations.Molecules 2019, 24 FOR PEER REVIEW  9 
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Under pure culture conditions, embryo hatching efficacy was altered by increasing concentrations of
MH. (A) Embryos were treated with increasing concentrations of MH for six days fro hour 5 (0–6 dpf).
MH concentrations of 5 µM and higher were r quired to cause a delay in t i g. Hatchability of
embryos from ix day MH (10 µM)-treatment was significantly decreas d in comparison to un reated
controls until 10 dpf. The external diff rences in appeara ce of the n wly hatched control frys n day
ten and the 10 µM MH-treated embryos were significantly obvious. (B) Embryos were treated with
increasing concentrations of MH for four days from stage 25 (2–6 dpf). MH concentrations of 10 µM
and higher were required to significantly cause a delay in hatching. Results are given as the mean
percentage of hatching efficiency ± SEM (n > 8 embryos for each condition). Statistical analysis was
performed by one-way ANOVA followed by Tukey’s post-hoc multiple comparison test. p < 0.05 was
considered as significant. The asterisk (*) indicates values significantly different from the control.
2.6. MH Regulates Wnt/β-Catenin Pathway during Cardiomyogenesis
Transcript levels of several Wnt/β-catenin signaling pathway proteins were altered in embryos
treated with 10 µM MH for six days (Figure 8). Wnt 1 mRNA expression was significantly increased
by MH. As shown in Figure 8, control and -treated embryos had similar levels of TGF-β2 mRNA
expr ssion, suggesting that MH could pot i ll romote cardiac fibrogenesis through the Wnt
signaling pathway.
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Figure 8. controls the Wnt signal transduction pathway, a main regulator of development. Real-time
RT-qPCR was performed on total RNA isolated from each group of embryos using described primers
in Table 1, leading to the amplification of the target gen . RT-qPCR analysis of Wnt 1, transforming
growth factor beta 2 (TGF-β2), frizzled 2 (Fzd2), low-density lipoprotein receptor-related protein 5 (LRP5),
dishevelled (Dvl), glycogen synthase kinase 3 beta (GSK-3β), β-catenin, and dickkopf 1 (DKK1) isolated
from the control and MH-treated embryos. Each value represents mean ± SEM (n = 100, replicated four
times). Statistical analysis was performed by two-way ANOVA followed by post-hoc Bonferroni test.
* indicates values which are significant versus the respective control group (p < 0.05).
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High expression levels of Fzd 2 (Wnt 1 receptor), LRP5 (Wnt 1 co-receptor), and Dvl were observed
in MH-treated embryos, but there was no difference in expression levels of glycogen synthase kinase-3
beta (GSK-3β), which is involved in the suppression of the Wnt/β-catenin and subsequent degradation
of beta-catenin (Figure 8). A significant increase was apparent in levels of β-catenin transcript of the
MH group. Increased β-catenin is implicated in ventricular myocyte proliferation control, while its
decrease leads to differentiation [23]. Thus, MH might inhibit cardiac differentiation via increased
endogenous β-catenin-mediated signaling during normal cardiac development.
Expression levels of dickkopf 1 (DKK1, a secreted Wnt/β-catenin pathway inhibitor) in the
MH-treated embryos were significantly higher compared to those of the control group (Figure 8).
MH-induced Wnt 1 overexpression enhanced the expression of several downstream molecules involved
in heart development. These molecules included Fzd 2, Dvl, LRP5, β-catenin (a downstream target
of LRP5), and DKK1. Collectively, MH clearly influenced the Wnt/β-catenin signaling pathway,
which had roles during various stages of cardiac development.
2.7. MH Prolongs Swimming Duration
The locomotion of embryos exposed to a sublethal concentration of MH was assessed two days
post hatching (Figure 9). Control fish showed clear response to the light-dark cycle while MH treatment
blunted this locomotor response (Figure 9).
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Figure 9. MH altered larvae’ locomotor responses to light and dark stimuli. Medaka larvae (2 days
post hatching (dph)) were monitored for 40 min (0–10 min dark, 10–20 min light, 20–30 min dark,
30–40 min light) using a ViewPoint Zebrabox. Duration of movements was measured at 2 min intervals
at a velocity of ≥2 mm/s. Larvae were treated with 5 µM, a sub-lethal concentration; MH and their
activity were measured in 10 min windows at the indicated time points. No significant (two-tailed
t-test, p < 0.05) increase in activity in MH-treated larvae (solid closed triangles, n = 14) was noted for
the time window during the light-cycle compared to baseline levels and that of the control group (solid
closed circles, n = 16). Each datum represents mean ± SEM of 16 observations.
3. Discussion
Much of our knowledge of the function of MH has been extrapolated from its analogs’ action and
its usage in the form of plant extracts in health and disease, which could provide a bias leading to
untoward side-effects. Compounds/drugs often have diverse and/or mixed effects from one organ
to another as well as across different disease states. The present study was aimed at demonstrating
the effects of MH and to establish its possible therapeutic utility. Many plant extracts have MH-like
molecules, but the effects of MH on cardiogenesis and neurogenesis have not been comprehensively
studied in contrast to cancer and inflammation. With increasing interest in honokiol related compound
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therapy, and their usage as supplements in diets and cosmetics, investigations were performed to
answer the following questions: (1) What was the effect of MH on known genes involved in cardiac
development and function in medaka embryos? (2) What were the morphological and physiological
effects of daily MH treatment in medaka embryos? (3) What was the effect on embryonic survival and
hatching of subjecting medaka embryos at different stages of cardiovascular development to various
concentrations of MH for different lengths of time? (4) Was MH a prothrombotic agent? (5) What was
the impact of sublethal concentration of MH on locomotion?
Fertilized eggs of medaka at two developmental stage windows (9–36 or 25–36) were exposed to
increasing concentrations of MH in an embryo medium. Our data showed that MH-induced embryonic
fatality was developmental-stage-specific. The embryos were more sensitive to MH at early stages of
development (9–25) than in late stages of development. MH-treated embryos exhibited cardiovascular
complications with a spectrum ranging from reduced blood flow to blood vessel occlusion, thrombus
formation, and slow heart rate.
In recent years, it has become apparent that the Wnt/β-catenin pathway (Wnt signaling pathway)
is essential for the regulation of numerous genes in embryogenesis [24], adult cell biology [25], tissue
homeostasis [26], and disease [27]. The canonical (known as the morphogen pathway) signaling of
this pathway is capable of upregulating the expression of a wide range of genes, which have roles in
giving rise to the majority of cardiomyocytes [28]. Targeted pathways related to Wnt include cardiac
differentiation [29] and cardiac remodeling [30]. Increased activated Wnt signaling has been recognized
as a major pathomechanism in heart and blood vessels [31]. Uncontrolled activation of the Wnt signaling
pathway has been implicated in the pathogenesis of cardiovascular disease [32] and inflammation [33].
The Wnt/β-catenin pathway not only has a major role in cardiovascular development, but it has been also
proven that a specific isoform of Wnt, Wnt-5A, functions in the process of neurogenesis and establishment
of functional connectivity [34], suggesting its tissue specificity. To understand why chronic MH treatment
may have undesirable effects in embryos, we investigated the effect of MH on the components of the
Wnt signaling pathway and its downstream targeted molecules, which may offer novel mechanistic
insights that could pave the way to enhancing its clinical utility.
Due to difficulties in the pharmacological approach and the absence of antibodies, quantification
of gene expression profiling of medaka cardiovascular tissues was the alternative approach to clarify
the role(s) MH plays in embryogenesis, and to assess the clinical utility of MH. MH-treated embryos
showed increased expression of the Wnt 1 gene (Figure 8). This deregulation of the Wnt signaling
pathway prompted us to target key members of this pathway, which had exhibited distinct temporal
and spatial profiles of expression during normal embryogenesis, post-surgery [35], and disease
states [36]. It has been established that when both the Fzd receptor and LRP5/6 form a complex
with Wnt ligands, the Wnt/β-catenin signaling pathway is activated [37]. Thus, we assessed the
effect of MH on the expression profile of Fzd receptors and co-receptor LRP5. MH upregulated the
expression levels of both Fzd and LRP5, suggesting Wnt/β-catenin signaling activation is sensitive to
MH concentration. Most importantly, the transcript level of Fzd was positively correlated with the
Wnt transcript expression level. Wnt-mediated Fzd/LRP5 stimulation leads to cytosolic β-catenin
accumulation. However, its accumulation and signaling are tightly regulated via Wnt-dependent and
Wnt-independent mechanisms [37]. Evidence shows that β-catenin signaling is essential for proper
vascular formation and the development and functioning of the heart [38]. Next, investigations were
performed to measure the expression pattern of β-catenin mRNA in MH-treated embryos. There was
an increase in β-catenin mRNA. Since β-catenin has a rapid turnover [37], we explored the expression
of GSK3β transcript. Evidence indicates that GSK3β activity is reduced/inactivated in the presence
of Wnt signal [37]. As shown in Figure 8, GSK3β expression was unaltered, which is critical to the
activation of β-catenin-mediated signaling. Moreover, our data suggested that MH had no direct effect
on GSK3β gene expression and the unaltered level of GSK3β might be due to overexpression of Wnt
levels, its binding to the complex of Fzd-LRP5, and stabilization of β-catenin [37]. Inactivation of
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GSK3β can result in the translocation of β-catenin to the nucleus and, subsequently, the induction of
β-catenin-dependent downstream target genes.
Urokinase plasminogen activator receptor (uPAR) [39] is one of these target genes downstream of
β-catenin that has roles in both thrombosis and complement system. tPA and uPA are two plasminogen
activators which are capable of catalyzing the activation of plasminogen. While uPA is required for
the generation of plasmin activity in tissue undergoing pathological remodeling, tPA is associated with
plasmin-induced activation of latent TGF-β in the vessel wall [40]. TGFβ2, a cytokine, is involved in
vascular function, and mutations in TGF β2 are found to be implicated in cardiovascular diseases such
as vascular complications and aortic disease [41]. The activity of uPA is regulated by its specific receptor,
uPAR [42]. The mRNA of PAI-1 and uPA were enhanced by MH treatment in medaka embryos, whereas
tPA mRNA steady-state levels were unaffected (Figure 5A). Similarly, TGFβ2 mRNA was unaffected
by MH (Figure 8). This coincides well with the finding in the vascular wall [40] that there is a potential
direct correlation between tPA expression and TGFβ2 gene expression and/or activation. The tPA/PAI-1
mRNA ratio was significantly decreased in the 10 µM MH group compared to the control. This suggests
that MH appears to influence the fibrinolytic system during embryogenesis. In addition, Dvl mRNA was
significantly elevated in MH-treated embryos. Overexpression of Dvl can inhibit the phosphorylation of
β-catenin by GSK3β leading to β-catenin stabilization, and can consequently promote expression of the
downstream targets. Overexpression of Dvl-1 in an atorvastatin-treated rat model of balloon-injured
carotid artery has been shown to reverse the treatment effects of atorvastatin on vascular smooth muscle
cells and collagen expression [43], suggesting the anti-restenosis action of Dvl. Collectively, these results
also confirm that there is a positive correlation between β-catenin increases and the level of downstream
target gene expression.
While DKK-1 is a transcriptional target of the p53 tumor suppressor [44] and β-catenin [45],
it plays a functionally redundant but protective role [46]. It is capable of suppressing the expression
of Wnt target genes [47] during postnatal angiogenesis [48]. MH causes an overexpression of the
DKK-1 gene in embryos. Our data has demonstrated that both the Wnt/β-catenin signaling and
its modulator, DKK-1, are increased in MH-treated embryos, highlighting their imbalance pattern
of expression. Evidence indicates that the overexpression of DKK-1 is markedly associated with
reduced cell proliferation [45], endothelial dysfunction, and concomitant platelet activation [49].
There is a positive correlation between DKK-1 expression and the recovery period following acute
myocardial infarction (MI) [50]. FVII, FX, and FXI were elevated in MH-treated embryos, suggesting
their consumption due to the activation of platelets. Activation of platelets lead to the formation of
thrombus and reduced blood flow, which was apparent in MH-treated embryos. It is well-established
that reduced blood supply to the myocardial tissues can result in ischemia and subsequent MI. On the
basis of plaque rupture, platelets are found to be the cellular source of DKK-1 in patients with acute ST
segment-elevated MI [51]. In addition, our study also demonstrates that MH is capable of upregulating
the gene expression of brain type natriuretic peptide (a secretory cardiac neurohormone, BNP) and
Troponin T, which has cardiac specificity and is essential for cardiac contractility [52]. There is a positive
correlation between elevated troponin levels and ST-segment elevation MI (STEMI) [52]. Elevated BNP
levels are a strong predictive marker of heart failure [53]. It is plausible to suggest that overexpression
of the components of the Wnt1/β-catenin dependent pathway by MH is due to heart failure and
ischemic areas in the embryo heart during the wound healing process following acute MI, whereas
MH-induced increased DKK-1 gene expression is mediated via platelet-induced endothelial activation.
Although this is the first work in the literature to have explored the effects of MH on inflammatory
cytokines in medaka, MH surprisingly caused robust increased levels of inflammatory markers such
as TNF-α and IL-1β (Figure 6) in contrast to those of honokiol and magnolol. Our study did not
address the differences we observed in the MH-mediated increased inflammatory mediators. We do
not have a ready explanation for the discrepancy regarding the cited anti-inflammatory action of MH
and that of our study. However, it is tempting to suggest that the elevation of these cytokines could
be the result of at least two potential explanation: (1) elevated inflammatory mediators in medaka
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embryos were the result of genetic differences passed down from parents in our medaka colony or
(2) the additive effect of MH on constitutive expression of the aforementioned cytokines in medaka
as previously seen in mouse embryos [54]. The underlying mechanism(s) for the increase in these
cytokines in MH-treated embryos remains uncertain. The increases in TNF-α and IL-1β are positively
correlated with the presence and extent of cardiac biomarkers level (Figure 5). There is a wealth of
knowledge about the association between heart failure and circulating inflammatory cytokines [55].
It is tempting to suggest that MH-induced inflammation might be the result of local tissue injury due
to lack of oxygen/nutrients or systemic inflammasome activation. However, further investigation is
needed to determine the potential causative role these inflammatory cytokines play in the progression
of MH-induced cardiac injury.
4. Materials and Methods
4.1. Medaka Maintenance and Breeding
All fish work was performed in compliance with animal ethics guidelines as given by the
Institutional Animal Care and Use Committee (IACUC) at the University of Mississippi according to
the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).
Embryos were collected in the morning and maintained on a 14 h:10 h light:dark cycle. The medium
or test solutions as well as plates were autoclaved or sterilized. All experiments with medaka embryos
were conducted in an embryo medium (17 mM NaCl, 0.4 mM KCl, 0.36 mM CaCl2, 0.6 mM MgSO4,
pH 7.4, and 0.0002% methylene blue) at 26 ± 1 ◦C.
Natural breeding or in vitro fertilization (known as squeezing) was used as a preferred method of
choice for generating embryos for pharmacological treatment experiments. The latter techniques were
used to generate embryos for most of our experiments, unless otherwise stated.
4.2. Extraction and Isolation of MH
The seeds of Magnolia grandiflora were collected at the University of Mississippi campus (MS 38677).
Air-dried powdered seeds (107 g) were soaked in EtOH (200 mL× 2× 24 h each). The combined extract
afforded oily material, where 2 g was subjected to centrifugal preparative thin layer chromatography
(CPTLC, Chromatotron®, Analtech Inc., Newark, DE, USA), using a 6 mm silica gel rotor. The sample
was dissolved in dichloromethane (DCM) and applied to the rotor under a rotation of 700 rpm,
and subsequently eluted with n-hexane, then DCM, to end up with MeOH (200 mL each). Eighteen
fractions were monitored and collected via TLC analysis (silica gel; solvents: n-hexane-EtOAc; 75:25).
The fractions were visualized by spraying the TLC plates, with 1% vanillin-H2SO4 used as a spray
reagent, where fractions 6 (361 mg) and 7 (36.0 mg) contained MH with a purity of 95% and 85%,
respectively, via LC and NMR analyses. Further purification of fraction 6 was completed using a
silica gel solid phase extraction cartridge (SPE) and was eluted with gradient of n-hexane/EtOAc
(100:0→99:1) with 0.1% increments to afford 10 fractions. The fractions were monitored and pooled
by TLC analysis (silica gel; solvents: n-Hex-EtOAc; 75:25), where fractions 7–9 afforded MH with
a purity of 95% via LC and NMR analyses. LC analysis was conducted using an Agilent 1100 high
performance liquid chromatography (HPLC) system equipped with a degasser (G1379A), quaternary
pump (G13311A), auto sampler (G1313A), column oven (G1316A), and UV-Diode detector (G1315B)
controlled by Chemstation software. Analysis of the fractions was carried out on an RP-C18 column
(150 × 4.6 mm; particle size 5 µm; Luna) with column oven temperature set to 25 ◦C and a gradient
system of eluent water (A) and acetonitrile (B) used. The gradient condition was as follows: 0–2 min
(10% B), 2–30 min (10% B→90% B), 30–35 min (100% B). The flow rate of the solvent was 1.0 mL/min
and the injection volume was 20 µL. All the analysis was carried out at wavelengths of 254, 280,
and 325 nm with a run time of 35 min. HPLC-grade acetonitrile and water solvents were used. Acetic
acid was added as a modifier to achieve a final concentration of 0.1% in each solvent. NMR spectra
were acquired on a Varian Mercury 400 MHz spectrometer at 400 (1H) and 100 (13C) MHz in CDCl3,
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using the residual solvent as an internal standard. Multiplicity determinations (DEPT) and 2D-NMR
spectra (HMQC, HMBC, and NOESY) were obtained using standard Bruker pulse programs.
4.3. MH Treatment
The up-and-down procedure (UDP) testing approach was used to determine the toxicity of MH
on medaka, beginning at stage 9 (hour 5) of embryological development (as delineated by [56,57])
(Figure 10). For the analysis of the effects of pharmacological treatments on cardiac rate, thrombus
generation, and blood vessel occlusion, fertilized eggs were collected within 5 h of mating and
immersed in embryo medium containing various concentrations of MH (1, 2, 5, 10, and 20 µM) and
0.02–0.04% DMSO (control group) in 48-well culture plates. The first batch of embryos (0–6 dpf, n = 8
to 12 embryos/group) was exposed to five different concentrations (1, 2, 5, 10, and 20 µM) of MH and
vehicle sample, 0.02–0.04% DMSO, which is known to be safe [58] and increase the permeability [59]
of the embryo’s chorion. The second batch of embryos (2–6 dpf) was exposed to similar dilutions
of MH (1, 2, 5, 10, and 20 µM) and 0.02–0.04% DMSO. All embryos were placed in a 48-well plate
with 1 mL of their respective dilutions. Both batches were monitored for changes in morphology,
delayed growth, behavior alteration, and mortality throughout the embryonic and larval-, juvenile-,
and adult-life stages.
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cha ber growth. The edaka heart begins beating and pu ping around 44 (stage 24) to 50 (sta e 25)
hours post fertilization. edaka e bryos ere treated with H either fro 0–6 days post fertilization
or 2–6 dpf at 26 ± ◦ .
E bryos and larvae ere raised in 48-well plates and maintained at a density of 1/1.0 L in
e bryo ediu ith daily ediu change. Groups of edaka e bryos, often nu bering 8 to 12,
were exposed for an exposure period from 0 to 6 days post fertilization (organogenesis period at stages
9 to 36–38), and 2 to 6 dpf (stages 25 to 36–38), with an interval of at least 24 h. Embryos/hatched
fry ere reared in nor al e bryo ediu at 6–10 dpf ithout ( ashed groups). Survivability,
hatching efficiency, blood vessel occlusion, and blood flo frequency ere observed until 10 dpf.
eart beats were counted on 3 and 6 dpf, and RNA isolation was immediately performed after 0–6 dpf
exposure. Behavioral experiments were conducted two days post hatching (dph) after 0–6 dpf MH
exposure. Larvae with no obvious malfor ation were used for locomotion experiments. Both embryos
and larvae were monitored daily by imaging.
4.4. Determination of MH Purity and MH Absorption in Medaka Embryos
The absorption of MH from embryo medium to embryos were ascertained after a single
concentration of MH (10 µM) for a period of 24 h using an Agilent 1290 Infinity series UHPLC
with a diode array detector and an Agilent 6120 quadrupole mass spectrometer (Agilent Technologies,
Santa Clara, CA, USA). The highly purified MH reference standard showed a base peak of [M + H]+
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281 with the APCI positive ionization mode; this ion was thus used in a selected ion monitoring mode
(SIM) to detect MH in the samples. Embryos were exposed to embryo medium containing 10 µM
MH from 5 h post fertilization (hpf) to 24 hpf. The disappearance of MH in the embryo’s bathing
(conditioned) medium was regarded as the absorption characterization of MH in the embryo toxicity
test and the cardiovascular toxicity test. The identity and concentration of MH in conditioned medium
was measured by UHPLC/MS.
The toxicity testing involved multi-stage exposure with repeated MH concentrations for six
consecutive days with an interval of at least 24 h. Six groups of embryos (n = 12/group) were
treated concurrently with 1, 2, 5, 10, and 20 µM MH and 0.02–0.04% DMSO (control group) at 5 hpf.
There was a washout period between each treatment to clear any remaining free MH and extruded
molecules into the conditioned embryo medium. The stock solution of MH was prepared in 100%
DMSO (Sigma-Aldrich, St. Louis, MO, USA). Treatment was done according to the design depicted in
Figure 10. In another set of experiments, hatched fry were reared in normal embryo medium without
MH until 10 dpf (washed groups).
4.5. Microscopy Study
Control and treated fish were sampled at various stages of development according to the treatment
schedule. Cardiovascular structure, blood flow, and heartbeat were analyzed under a microscope.
Images were acquired on a Nikon TI2-E inverted microscope with a white light LED illuminator and
a sCMOS Cooled Monochrome Camera. Videos were captured using Nikon Elements automated
acquisition at a rate of 20 frames per second for one minute.
4.6. Locomotion Study
The free-swimming behavior of MH-treated larvae was compared to that of the control group.
MH was prepared at a 5 µM concentration in embryo medium. This concentration was selected on
the basis of LC50 studies. The effects of acute MH exposure on locomotor activity in larvae were
examined at 2 dph. We assessed activity in 24-well plates. Larvae were placed individually in wells
containing 2 mL of embryo medium. The larvae acclimatized to the darkness of the Zebrabox over
20 min (Viewpoint, Montreal, Canada) before the start of the locomotion experiment. The duration of
movements was measured at a velocity of ≥2 mm/s.
4.7. RNA Extraction
The isolated heart of the medaka embryo from the 6 dpf control and MH-treated embryos was
too small to obtain from it enough total RNA for the quantification of target genes. To overcome this
problem, 100 embryos from the 6 dpf control and MH-treated embryos were pooled into one sample
and RNA was extracted using an RNAeasy micro kit (QIAGEN GmbH) following the manufacturer’s
protocol. However, samples were replicated four times.
4.8. Reverse Transcription—Quantitative Polymerase Chain Reaction (RT-qPCR)
One microgram of total RNA extracted from each sample were reverse-transcribed into cDNA
using a Quantitect RT kit (QIAGEN GmbH). Quantitative expression profiles of the genes of interest
were analyzed using SYBR Green (Invitrogen, Carlsbad, CA, USA) according to the instructions of the
manufacturer. Primers used for the amplification of each gene have been tabulated in Table 1.
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Table 1. Oligonucleotide sequences used in this study.
Gene Sense (5′-3′) Antisense (3′-5′) Product Size (bp) Reference
eEf1α GGAGGCCAGCGACAAGAT GCGAGAAGGTGGCAGGAT 115 NM_001104662.1
FX TGTCAAAGCCCTGTGTGAAT AGAAATGTTCACAGCCACCA 147 XM_020710825.1
FXI GAAGGATAATGCAGACCAGTGTC GATGACACCCTTCAAGTAGCATC 127 XM_004074394.4
FVII GTTCTGTCGGATAGGTGGATTT CCTCCAGGTCATGTTTACCTAC 97 XM_004066449.3
PAI-1 ATGCCGAGGTTTTCTCTGAAC GTTGAACATGTCTCCCAGTCC 78 XM_020711407.1
uPA ACTGTGTTTCTGGGAAAGAGTG GGATGATCATTTTCTCCACGGT 82 XM_004077409.4
tPA CAGCCCCGATCCAAGC CCCTTCCATCGCAGCC 185 XM_011478844.3
ATRAP CATGTGGGGGAACTTCAGC GCCCACCAGAAACATGAGG 91 XM_011475678.2
ETB CTGATCTTTGTGGTGGGCAT CCCATTCCTCATGCACTTGT 78 NM_001104844.1
IL-1β CTGTTTCTGGAGGAGGTGG AGAAGAGGAAGCGCACATT 79 XM_011478737.2
TNF-α AACCGAAGAGTCTGAGAGGG AGCTGAAGAAGAGTACCGCT 105 XM_004074335.3
Catalase TGCTAGCAGTTGATTGTCTGT CACAGATCCACTGAAACAGGA 100 XM_004069460.2
GPX2 TCAACGGAGTAAACACGCAT GATCCTGCATGAGAGAGCTG 90 XM_004082594.3
GST A CTGAAGGAGAGCGGCAC CAGGAACGAGCCAGAGC 107 XM_020710769.1
SOD2 AAATGTGCGTCCTGACTATGT TTTTGGCTATCTGAAGACGCT 83 XM_004083471.3
Wnt1 CCAGAAAACCCAGCTCACAA TTGTGGGAGCAGAAGTTTGG 80 XM_020704658.1
FZd2 CACATGACCCCAGACTTCAC AGAAACCAGAAGTGATGCCG 76 XM_020705151.1
LRP5 GAAGGCCCGAGCAGTTCA AAGACATGGCTCCGTCGT 101 XM_011472833.2
Dvl TGCTGAAACAAAGCCCAAAGT ACCTCAAGGATCTGAGTGAGC 87 XM_011490628.3
β-catenin CACAGAACTCCTACACAGCC AGGCGCTTCTTGTAGTCTTG 102 XM_004077778.3
DKK1 GTGACACATGCCTGAGATCG CACAGGCTTACAGATGCGAG 83 XM_020709512.1
GSK3β AGCTGCAGATTATGAGGAAGTTG TAGACGGTCTCTGGAACATAGTC 130 XM_023950884.1
ErbB3 GAGGTTGAGAAGGATGGCGT CTACCTGGACTTCCTGTGCC 86 XM_011474665.3
NRG-2 CTCGTCACTGTGGGGGA CTCGTCAGTGGGGTCCA 93 XM_020708867.2
BNP A GAGCTCTGTTGATGAGGAGG CAGTCCTGGCTCATCTTCTC 88 NM_001104685.2
Troponin T GAGCTCTGTTGATGAGGAGG GCTGATCCGGTTTCTGAGT 362 XM_004068713.4
FoxO1 GCCCATGCCAGTTCTGAGTA ATCCTCCGTGTTGGTGGATG 102 XM_011485361.2
TGF-β2 GTTACTCCGACCTGAGGAAGATAG TGACACCCAATCTTTAACGGTTTC 127 XM_004073149.3
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Quantification of target genes were done using an ABI 7000 real-time PCR machine (Applied
Biosystems, Inc., Foster City, CA, USA). To measure the relative quantity of target genes per 1 µg of
the total RNA from each group, a 2−∆∆Ct method was used. On the basis of McCurley and Callard’s
2008 study [60] as well as our own observations, eEf1α was included as an internal control. Samples
were replicated four times. Quantitative expression data were used as the basis for making the major
interpretations of this study.
4.9. Statistical Analyses
Statistical analysis was performed using Graph Pad Prism V6.0. Data are presented as
mean ± SEM. Morphological data were analyzed by one-way ANOVA followed by Tukey’s post-hoc
multiple comparison test where more than two groups were compared. The LC50 was calculated by
log transformed data using nonlinear regression (curve-fit) (GraphPad Prism). Statistical analysis for
all RT-qPCR data was performed by two-way ANOVA followed by post-hoc Bonferroni test. Data for
locomotion study were analyzed by two-tailed t-test. A difference between two means was considered
to be significant when p < 0.05 (* p < 0.05).
5. Conclusions
Natural product extracts play complex roles in cardiovascular homeostasis. They can have
protective and exacerbating effects on diseases due to the presence and complexity of plant extract
composition. There has been very little information produced about the pharmacodynamics and
pharmacokinetics [61] of MH, particularly in regard to both its teratogenic and cardiovascular effects.
The typical recommended levels of magnolia bark extracts range from 200–800 mg/day/person [62].
The potential effects of MH on embryonic development are prominently apparent in our current
study (Figure 11). Since medaka can be used to model the human cardiovascular system [57], here we
report that MH alone is harmful to embryos because of its proinflammatory and prothrombotic
properties as well as its effects on the Wnt signaling pathway. Unfortunately, little is known about the
contribution(s) of MH once the trajectory has been set following its ingestion in humans. Our evidence
is not sufficiently robust to support and extrapolate its deleterious effects in humans. However,
we suggest that its inclusion in plant extracts could potentially retard the beneficial effects of other
components of magnolia bark extracts or others. Herbal medicine optimization research must take MH
levels into consideration in order to prevent the stimulation of both stress-induced pathways and the
Wnt signaling pathway, which plays major roles in the control of all facets of embryonic development.
Complementary approaches are needed to have a better understanding of the effects of maternal use
of plant extracts containing MH on the offspring’s health during pregnancy.
Molecules 2019, 24, 475 17 of 21
Molecules 2019, 24 FOR PEER REVIEW  18 
 
 
Figure 11. Flowchart depicting MH treatment induces cellular and morphological changes in medaka 
embryos that lead to inflammation, thrombosis, spinal, and cardiac deformities. Solid arrows indicate 
the direction of the effects of MH on indicators of increased inflammation/cardiovascular risk and the 
anatomic locations as well as a link with the prior object/event. The flow of physiological changes that 
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GST A Glutathione S-transferase A
hpf Hours post fertilization




PAI-1 Plasminogen activator inhibitor 1
SOD2 Superoxide dismutase 2
STEMI ST-segment elevation MI
tPA Tissue plasminogen activator
UHPLC/MS Ultra-high performance liquid chromatography/mass spectrometer
u-PA Urokinase plasminogen activator
uPAR Urokinase plasminogen activator receptor
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Figure A1. Examples of images representing the medaka phenotype following MH treatment. 
Medaka embryos were treated with 10 μM MH or an untreated control batch (0.02% DMSO) for 0–6 
dpf or 2–6 dpf following the same protocol as described in the method. (A) Control. No phenotypic 
abnormality was detected with the control for the two groups. This first image displays an example 
of a typical control obtained immediately for both treatment plans. (B) This is an example of a typical 
medaka treated with 10 μM MH for 0–6 dpf. Curved tail phenotypes were observed in many. (C) 
Edema phenotypes were observed in medaka treated with 10 μM MH for 2–6 dpf. Bent tail 
phenotypes were observed in few. 
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The effect of MH on heart function. These videos show how the medaka heart functions 
normally (Video 1) and when it is exposed to 10 μM MH for six days of treatment from 5 h. 
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Figure A1. Examples of images representing the medaka phenotype following MH treatment. Medaka
embryos were treated with 10 µM MH or an untreated control batch (0.02% DMSO) for 0–6 dpf or 2–6 dpf
following the same protocol as described in the method. (A) Control. No phenotypic abnormality was
detected with the control for the two groups. This first image displays an example of a typical control
obtained immediately for both treatment plans. (B) This is an example of a typical medaka treated with
10 µM MH for 0–6 dpf. Curved tail phenotypes were observed in many. (C) Edema phenotypes were
observed in medaka treated with 10 µM MH for 2–6 dpf. Bent tail phenotypes were observed in few.
Appendix B
The effect of MH on heart function. These videos show how the medaka heart functions normally (Video 1)
and when it is exposed to 10 µM MH for six days of treatment from 5 h.
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